Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.
2.

Determination of coumarin metabolism in Turkish population.

Cok I, Aygün Kocabaş N, Cholerton S, Karakaya AE, Sardaş S.

Hum Exp Toxicol. 2001 Apr;20(4):179-84.

PMID:
11393269
3.

Variability of coumarin 7- and 3-hydroxylation in a Jordanian population is suggestive of a functional polymorphism in cytochrome P450 CYP2A6.

Hadidi H, Irshaid Y, Vågbø CB, Brunsvik A, Cholerton S, Zahlsen K, Idle JR.

Eur J Clin Pharmacol. 1998 Jul;54(5):437-41.

PMID:
9754990
4.

Interindividual variability of coumarin 7-hydroxylation in healthy volunteers.

Rautio A, Kraul H, Kojo A, Salmela E, Pelkonen O.

Pharmacogenetics. 1992 Oct;2(5):227-33.

PMID:
1306122
5.

Variation in coumarin 7-hydroxylase activity associated with genetic polymorphism of cytochrome P450 2A6 and the body status of iron stores in adult Thai males and females.

Ujjin P, Satarug S, Vanavanitkun Y, Daigo S, Ariyoshi N, Yamazaki H, Reilly PE, Moore MR, Kamataki T.

Pharmacogenetics. 2002 Apr;12(3):241-9.

PMID:
11927840
6.

A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502).

Nunoya K, Yokoi T, Kimura K, Inoue K, Kodama T, Funayama M, Nagashima K, Funae Y, Green C, Kinoshita M, Kamataki T.

Pharmacogenetics. 1998 Jun;8(3):239-49.

PMID:
9682269
7.
8.

Coumarin metabolism by rat esophageal microsomes and cytochrome P450 2A3.

von Weymarn LB, Murphy SE.

Chem Res Toxicol. 2001 Oct;14(10):1386-92.

PMID:
11599930
9.

CYP2A6: a human coumarin 7-hydroxylase.

Pelkonen O, Rautio A, Raunio H, Pasanen M.

Toxicology. 2000 Apr 3;144(1-3):139-47. Review.

PMID:
10781881
11.

Inhibition of coumarin 7-hydroxylase activity in human liver microsomes.

Draper AJ, Madan A, Parkinson A.

Arch Biochem Biophys. 1997 May 1;341(1):47-61.

PMID:
9143352
12.

Single-dose disulfiram does not inhibit CYP2A6 activity.

Kharasch ED, Hankins DC, Baxter PJ, Thummel KE.

Clin Pharmacol Ther. 1998 Jul;64(1):39-45.

PMID:
9695717
13.
14.

Spectrofluorometric analysis of CYP2A6-catalyzed coumarin 7-hydroxylation.

Waxman DJ, Chang TK.

Methods Mol Biol. 1998;107:111-6. No abstract available.

PMID:
14577218
15.

CYP2A13-catalysed coumarin metabolism: comparison with CYP2A5 and CYP2A6.

von Weymarn LB, Murphy SE.

Xenobiotica. 2003 Jan;33(1):73-81.

PMID:
12519695
16.

In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais.

Peamkrasatam S, Sriwatanakul K, Kiyotani K, Fujieda M, Yamazaki H, Kamataki T, Yoovathaworn K.

Drug Metab Pharmacokinet. 2006 Dec;21(6):475-84.

17.
18.

Effect of cigarette smoking on coumarin metabolism in humans.

Poland RE, Pechnick RN, Cloak CC, Wan YJ, Nuccio I, Lin KM.

Nicotine Tob Res. 2000 Nov;2(4):351-4.

PMID:
11197315
19.

A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles.

Fernandez-Salguero P, Hoffman SM, Cholerton S, Mohrenweiser H, Raunio H, Rautio A, Pelkonen O, Huang JD, Evans WE, Idle JR, et al.

Am J Hum Genet. 1995 Sep;57(3):651-60.

20.

Supplemental Content

Support Center